BioInsights - Manufacturing of RCA-free adenoviral vectors

Manufacturing of RCA-free adenoviral vectors

Cell & Gene Therapy Insights 2022; 8(3), 351;

10.18609/cgti.2022.052

Published: 27 March 2022
Poster
Nico Scheer


Adenoviral vectors are frequently used as delivery tools for vaccine and gene therapy applications. Once such vectors have infected a target cell, it is of utmost importance that they do not spread further in a patient‘s body. Therefore, avoiding the occurrence and further propagation of replication-competent adenovirus (RCA) during production is crucial. Since the risk of RCA occurrence depends on the adenoviral vector and the cell line used for virus stock generation and manufacturing, selecting an appropriate cell line and production platform is critical.